Siemens Healthineers, a Germany-based medical device company and a subsidiary of multinational conglomerate Siemens, has announced plans to invest $428m (€396.06m) to open a new in-vitro diagnostics manufacturing facility in Shanghai, China.
The move comes after Siemens Healthineers split its Asia-Pacific operations into two in October 2022, “to allow both China and the rest of the region to achieve their full potential”. The Chinese operations are headed by Jerry Wang – who had been in charge of the whole of Asia – while the new Asia-Pacific Japan region is headed by Vy Tran, formerly Varian’s chief compliance and quality officer.
Go deeper with GlobalData
The history of Siemens Healthineers can be traced back to the mid-18th century as an arm of the Siemens parent group. It has been known as Siemens Healthcare, Siemens Medical Solutions and Siemens Medical Systems. It was rebranded as Siemens Healthineers in 2016, and the companies it owns across the world have some 69,500 employees.
